Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C
Département d'Information Médicale, Hospices Civils de Lyon, France.
J Viral Hepat. 2001 Mar;8(2):87-95. doi: 10.1046/j.1365-2893.2001.00280.x.
This study assessed the sensitivity and specificity of third-generation serological hepatitis C diagnostic tests from an analysis of the literature. The literature analysis was run using criteria from McMaster University for the assessment of diagnostic tests. The selected studies were grouped according to the type of population at high and low risk for hepatitis C virus (HCV) infection and to the type of reference test. The homogeneity of the sensitivity and the specificity was tested in each group using a Fisher's exact test. Of 132 studies, 10 were selected. When the estimates were homogeneous, summary point estimates and confidence intervals were computed; when the estimates were heterogeneous, subgroup analysis was performed. The sensitivity of third-generation enzyme-linked immunosorbent assay (ELISA3) was estimated at 98.9% (95% CI: 94-100%) in patients with chronic liver disease and at 97.2% (95% CI: 92-99%) in panels of sera. ELISA3 specificity was found at 100% in patients with chronic liver disease. The sensitivity of the third generation recombinant immunoblot assay (RIBA3) was assessed at 78.8% (95% CI: 65-89%) in haemodialysed patients. This analysis provides evidence for the good sensitivity and specificity of ELISA3 assays particularly in high risk patient groups and confirms their use for screening in these populations. Further studies are needed to assess properly RIBA3 in general population and in risk patients.
本研究通过对文献的分析评估了第三代丙型肝炎血清学诊断试验的敏感性和特异性。文献分析采用了麦克马斯特大学评估诊断试验的标准。所选研究根据丙型肝炎病毒(HCV)感染高风险和低风险人群的类型以及参考试验的类型进行分组。使用Fisher精确检验对每组的敏感性和特异性的同质性进行检验。在132项研究中,选取了10项。当估计值具有同质性时,计算汇总点估计值和置信区间;当估计值具有异质性时,进行亚组分析。第三代酶联免疫吸附测定(ELISA3)在慢性肝病患者中的敏感性估计为98.9%(95%CI:94 - 100%),在血清组中的敏感性为97.2%(95%CI:92 - 99%)。ELISA3在慢性肝病患者中的特异性为100%。第三代重组免疫印迹法(RIBA3)在血液透析患者中的敏感性评估为78.8%(95%CI:65 - 89%)。该分析为ELISA3检测具有良好的敏感性和特异性提供了证据,尤其是在高风险患者群体中,并证实了其在这些人群中用于筛查的用途。需要进一步研究以在一般人群和风险患者中正确评估RIBA3。